Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1675350

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1675350

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2025-2033

PUBLISHED:
PAGES: 142 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2999
PDF & Excel (5 User License)
USD 3999
PDF & Excel (Corporate License)
USD 4999

Add to Cart

The global non-alcoholic steatohepatitis (NASH) market size reached USD 1.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.5 Billion by 2033, exhibiting a growth rate (CAGR) of 22.97% during 2025-2033. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

Non-Alcoholic Steatohepatitis (NASH) Market Trends:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.

Key Market Segmentation:

Drug Type Insights:

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others

Disease Cause Insights:

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity

Sales Channel Insights:

  • Hospital Pharmacy
  • Online Providers
  • Retail Pharmacy

End User Insights:

  • Hospitals
  • Clinics
  • Homecare Settings

Regional Insights:

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1.How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 2.What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2025-2033?
  • 3.What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 4.What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 5.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
  • 6.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
  • 7.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
  • 8.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
  • 9.What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 10.Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?
Product Code: SR112025A7397

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Product Code: SR112025A7397

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2024
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2024
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2024
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million USD), 2025-2033
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million USD), 2025-2033
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!